V.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

Lone, isolated, free-flowing pleural effusion on imaging. See other forms of pleural effusions under Vb, d, e, g, h, i, m which may present similarly on imaging. The effusion can be uni- or bilateral. More often a lymphocyte-, mixed or neutrophil-rich exudate. At times the effusion is eosipophil-rich. Pleural effusion can be present with the acute clinical phase of severe drug-induced ILD (e.g. methotrexate lung; PMID 16840219). In general, pleural effusion in the context of drug-induced ILD or pulmonary edema is not tabulated under this heading. ANA-panel indicated to diagnose drug-induced lupus PMID 10424528

Last update : 01/01/1970
 

Causative drugs

112

Penicillamine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH)
III.b III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.b - Pneumorenal syndrome (w/wo ANCAs)
III.d III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.d - Alveolar hemorrhage, diffuse (ANCA-positive/-related)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc, XVx)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis - Myasthenic-like syndrome
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba)
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)
XI.t XI - Miscellaneous
XI.t - Yellow nail syndrome
XV.z XV - Pathology
XV.z - Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn)
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
1

Radiation therapy (early effects)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
I.ab I - Interstitial/parenchymal lung disease
I.ab - Radiation-induced lung injury (RILI)
I.ac I - Interstitial/parenchymal lung disease
I.ac - Acute radiation pneumonitis
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax
VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
IX.h IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.h - Dyspnea, unexplained otherwise
XII.k XII - Cardiovascular involvement / toxicity
XII.k - Constrictive pericarditis - Pericardial thickening
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern
XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
2

Radiation therapy (medium term & late effects)

I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
I.o I - Interstitial/parenchymal lung disease
I.o - Focal/localized area of pneumonitis/fibrosis
I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence
I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis
IV.h IV - Airway involvement
IV.h - Large airway necrosis
IV.k IV - Airway involvement
IV.k - Bronchiectasis
IV.m IV - Airway involvement
IV.m - Bronchial stenosis/stricture
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax
V.l V - Pleural and/or pericardial involvement
V.l - Malignant pleural mesothelioma
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)
V.t V - Pleural and/or pericardial involvement
V.t - The apical cap
VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease
VI.t VI - Pulmonary vasculopathies
VI.t - Pulmonary artery aneurysm(s)
VI.ab VI - Pulmonary vasculopathies
VI.ab - Pulmonary artery stenosis
VII.d VII - Mediastinal involvement
VII.d - Fibrosing mediastinitis
VII.i VII - Mediastinal involvement
VII.i - Mediastinitis
VII.j VII - Mediastinal involvement
VII.j - Compression of mediastinal structures/organs
VII.l VII - Mediastinal involvement
VII.l - Calcification of mediastinal lymph nodes
VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.j VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.j - Laryngeal disorder-Laryngeal nerve palsy (dysphonia, hoarseness)
VIII.r VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.r - Tracheal/large airway necrosis, chondronecrosis, perforation
VIII.t VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.t - Vocal cord paresis/paralysis
VIII.ab VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ab - Airway (e.g. tracheoesophageal) fistula
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.aj IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.aj - Paraspinal muscle myositis/myopathy/neuromyopathy +- the dropped head syndrome
XI.g XI - Miscellaneous
XI.g - Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)
XI.h XI - Miscellaneous
XI.h - Esophageal pathology (erosion, ulcer, tear, rupture, fistula)
XI.i XI - Miscellaneous
XI.i - Esophageal toxicity
XI.p XI - Miscellaneous
XI.p - Chest deformity: platythorax
XI.v XI - Miscellaneous
XI.v - Rib fracture
XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture
XI.ax XI - Miscellaneous
XI.ax - Esophageal stenosis/stricture
XI.bb XI - Miscellaneous
XI.bb - Aorto-esophageal fistula
XI.bs XI - Miscellaneous
XI.bs - Dropped-head syndrome
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure
XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction
XII.k XII - Cardiovascular involvement / toxicity
XII.k - Constrictive pericarditis - Pericardial thickening
XII.o XII - Cardiovascular involvement / toxicity
XII.o - Coronary artery disease (subacute, chronic)
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ad XII - Cardiovascular involvement / toxicity
XII.ad - Effusive-constrictive pericarditis
XII.ak XII - Cardiovascular involvement / toxicity
XII.ak - Late left ventricular dysfunction/failure
XII.an XII - Cardiovascular involvement / toxicity
XII.an - Pericardial calcification
XII.bc XII - Cardiovascular involvement / toxicity
XII.bc - Coarctation of the aorta (acquired)
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XIII.d XIII - Neoplastic conditions
XIII.d - Malignant mesothelioma (pleural, pericardial)
XIII.e XIII - Neoplastic conditions
XIII.e - Breast cancer
XIII.j XIII - Neoplastic conditions
XIII.j - Pulmonary synovial sarcoma
XIII.l XIII - Neoplastic conditions
XIII.l - Chondrosarcoma
XIII.m XIII - Neoplastic conditions
XIII.m - Tumor of the heart
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.l XV - Pathology
XV.l - Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.bi XVI - Imaging
XVI.bi - Imaging: Hyperlucent lung
XVI.bj XVI - Imaging
XVI.bj - Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)
3

Radiation therapy to the chest

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.o I - Interstitial/parenchymal lung disease
I.o - Focal/localized area of pneumonitis/fibrosis
I.v I - Interstitial/parenchymal lung disease
I.v - Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence
I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.h III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.h - Major/massive hemoptysis
IV.h IV - Airway involvement
IV.h - Large airway necrosis
IV.m IV - Airway involvement
IV.m - Bronchial stenosis/stricture
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax
V.k V - Pleural and/or pericardial involvement
V.k - Pleural calcifications
VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease
VI.x VI - Pulmonary vasculopathies
VI.x - Pulmonary lymphangiectasis
VII.d VII - Mediastinal involvement
VII.d - Fibrosing mediastinitis
VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.r VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.r - Tracheal/large airway necrosis, chondronecrosis, perforation
VIII.t VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.t - Vocal cord paresis/paralysis
VIII.ab VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ab - Airway (e.g. tracheoesophageal) fistula
IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.h XI - Miscellaneous
XI.h - Esophageal pathology (erosion, ulcer, tear, rupture, fistula)
XI.i XI - Miscellaneous
XI.i - Esophageal toxicity
XI.j XI - Miscellaneous
XI.j - Esophageal dysmotility
XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases
XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture
XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction
XII.k XII - Cardiovascular involvement / toxicity
XII.k - Constrictive pericarditis - Pericardial thickening
XII.o XII - Cardiovascular involvement / toxicity
XII.o - Coronary artery disease (subacute, chronic)
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XIII.e XIII - Neoplastic conditions
XIII.e - Breast cancer
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern
XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)
XV.bm XV - Pathology
XV.bm - Path: Diffuse lymphangiectasis
XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.af XVII - Infections & related conditions
XVII.af - Reactivation of a prior pulmonary infection (TB, melioidosis)
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
3

Sertraline

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
V.ad V - Pleural and/or pericardial involvement
V.ad - Pleural effusion and drug-induced ILD
VI.g VI - Pulmonary vasculopathies
VI.g - Foreign body pulmonary vasculopathy (Excipient lung disease)
VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
1

Statins

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE)
I.ar I - Interstitial/parenchymal lung disease
I.ar - The association of ILD and myositis
IV.d IV - Airway involvement
IV.d - Cough (lone)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax
VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.ac IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ac - Myositis of the respiratory muscles (May lead to respiratory muscle paralysis)
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba)
X.ba X - Systemic/Distant conditions, syndromes and reactions
X.ba - Rhabdomyolysis (see also under Xj)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XII.ab XII - Cardiovascular involvement / toxicity
XII.ab - Pericardial fat necrosis
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern
XV.o XV - Pathology
XV.o - Path: Endogenous lipoid pneumonia (phospholipidosis)
XV.ap XV - Pathology
XV.ap - Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)
XV.co XV - Pathology
XV.co - Path: Foamy inclusions in alveolar macrophages and/or in other lung cells
XVI.bx XVI - Imaging
XVI.bx - Imaging: Waxing and waning nodules
XIX.f XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.f - BAL: Foamy macrophages
1

Sulfamides - Sulfonamides

1

Sulfasalazine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic
IV.y IV - Airway involvement
IV.y - Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)
VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant)
XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis
XIV.a XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.a - Methemoglobinemia
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.k XV - Pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XV.ac XV - Pathology
XV.ac - Path: Pulmonary vasculitis other than capillaritis
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
1